Arie Belldegrun - Kite Pharma Chairman

Chairman

Dr. Arie S. Belldegrun, M.D., FACS., is Executive Chairman of the Board, President, Chief Executive Officer, Founder of the Company. He was also appointed to serve as our President and Chief Executive Officer, an interim position he held since December 2013. Dr. Belldegrun currently serves as Chairman of Arno Therapeutics, Inc., a biopharmaceutical company, a position he has held since March 2008, as Chairman of UroGen Pharma Ltd., a pharmaceutical company, a position he has held since December 2012, and as Chairman and Partner of Two River Consulting, LLC, a consulting firm, since June 2009. He served as a Director of Teva Pharmaceutical Industries Ltd., a pharmaceutical company, from March 2013 to January 2017. He also served as a Director of Nile Therapeutics, Inc., a biotechnology company, from September 2009 to November 2013 and as a Director of SonaCare Medical, LLC, a healthcare company, from October 2009 to October 2014. In 1996, he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman from 1996 to 2001, and continued to serve on the board until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding ViceChairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009 when it was acquired by Johnson Johnson. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA in October of 1988, since 2014.
Age 66
Tenure 10 years
Phone310 824-9999
Webwww.kitepharma.com

Arie Belldegrun Latest Insider Activity

Tracking and analyzing the buying and selling activities of Arie Belldegrun against Kite Pharma stock is an integral part of due diligence when investing in Kite Pharma. Arie Belldegrun insider activity provides valuable insight into whether Kite Pharma is net buyers or sellers over its current business cycle. Note, Kite Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kite Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Kite Pharma Management Efficiency

Kite Pharma's management efficiency ratios could be used to measure how well Kite Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Found 8 records

CHAIRMAN Age

Clint GartinMorgan Stanley
N/A
James GormanMorgan Stanley
66
William DoranSEI Investments
83
Marcelo OdebrechtBraskem SA Class
N/A
Alfred WestSEI Investments
81
Marcelo LyrioBraskem SA Class
55
Joao CoxBraskem SA Class
57
Ernani CarvalhoBraskem SA Class
68
Kite Pharma, Inc., a clinicalstage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. Kite Pharma (KITE) is traded on NASDAQ Exchange in USA and employs 184 people.

Management Performance

Kite Pharma Leadership Team

Elected by the shareholders, the Kite Pharma's board of directors comprises two types of representatives: Kite Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kite. The board's role is to monitor Kite Pharma's management team and ensure that shareholders' interests are well served. Kite Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kite Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ran Nussbaum, Independent Director
Jonathan Peacock, Independent Director
Shawn Tomasello, Chief Commercial Officer
Jian Irish, Senior Vice President - Supply Chain
Cynthia Butitta, CFO and COO
Franz Humer, Director
Timothy Moore, Executive Vice President - Technical Operations
Jeffrey Wiezorek, Vice President - Clinical Development
Ian Clark, Independent Director
Steven Ruchefsky, Independent Director
Joshua Kazam, Director
Helen Kim, Executive Vice President - Business Development
Helen MBA, Executive VP of Bus. Devel.
David Bonderman, Lead Independent Director
David Chang, Executive Vice President - Research and Development, Chief Medical Officer
Arie Belldegrun, Executive Chairman of the Board and Presidentident, CEO, Founder
Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
Owen Witte, Director
Paul Jenkinson, CFO
Marc Better, VP of Translation Medicine
Farah Champsi, Independent Director
Roy Doumani, Independent Director
Rizwana Sproule, Vice President - Regulatory Affairs
Margo Roberts, Chief Scientific Officer

Kite Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kite Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kite Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kite Pharma's short interest history, or implied volatility extrapolated from Kite Pharma options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in Kite Stock

If you are still planning to invest in Kite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kite Pharma's history and understand the potential risks before investing.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments